Bullous Pemphigoid
Bullous Pemphigoid Market

Bullous Pemphigoid (BP) is an acquired, rare autoimmune skin disorder.  It is a subepidermal bullous disease where autoantibodies are directed against the skin’s basement membrane zone components. 


Bullous Pemphigoid Epidemiological Segmentation 


The Epidemiological Segmentation of Bullous Pemphigoid in the 7MM from 2018 to 2030 is segmented into:-


  • Diagnosed Prevalent cases of Bullous Pemphigoid
  • Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid
  • Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid
  • Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid


Bullous Pemphigoid Epidemiological Insights Observed in 2020


  • The total diagnosed prevalent cases of Bullous Pemphigoid in 7MM were found to be 124,517.
  • The diagnosed prevalent cases of Bullous Pemphigoid in the United Kingdom were observed to be 24,644.
  • The diagnosed prevalent cases of Bullous Pemphigoid in France were 23,843.
  • The diagnosed prevalent cases of Bullous Pemphigoid in Germany were found to be 17,626.
  • The diagnosed prevalent cases of Bullous Pemphigoid in Spain were observed to be 10,920.
  • The diagnosed prevalent cases of Bullous Pemphigoid Japan were observed to be 8,619.
  • In the United States, the Age-specific Diagnosed Prevalent cases of Bullous Pemphigoid in males were found to be 11,018, whereas in females, it was observed to be 14,023.


Bullous Pemphigoid Market


The market size of Bullous Pemphigoid in the 7MM was found to be USD 151 Million in 2020.


Bullous Pemphigoid Market Drivers

  • Robust emerging pipeline
  • Ubiquitous prevalence
  • Precise diagnostic procedures 


Bullous Pemphigoid Market Barriers

  • Complications associated with available therapies
  • Delayed diagnosis
  • Polypharmacy
  • Lack of disease awareness 


Bullous Pemphigoid Emerging Drugs


The emerging drugs of the Bullous Pemphigoid market are


  • Dupilumab (Dupixent)
  • Nomacopan (rVA576, Coversin)
  • iCo-008 (Bertilimumab)
  • Avdoralimab (IPH5401)
  • Fasenra (benralizumab)
  • AKST4290, and others


Bullous Pemphigoid Key Players


The key players working in the Bullous Pemphigoid market are 


  • Regeneron Pharmaceuticals
  • Sanofi
  • Akari Therapeutics
  • Immune Pharmaceuticals
  • iCo Therapeutics
  • Innate Pharma
  • AstraZeneca
  • Alkahest Inc.
  • Grifols, and others